Neumora Therapeutics, Inc. Common Stock (NMRA) is a publicly traded Healthcare sector company. As of May 21, 2026, NMRA trades at $1.78 with a market cap of $327.95M and a P/E ratio of -1.18. NMRA moved +3.59% today. Year to date, NMRA is +5.20%; over the trailing twelve months it is +135.71%. Its 52-week range spans $0.61 to $17.19. Analyst consensus is strong buy with an average price target of $9.33. Rallies surfaces NMRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NMRA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. NMRA recently traded at $1.78. Market cap is $327.95M. P/E ratio is -1.18. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $1.78 |
| Market Cap | $327.95M |
| P/E Ratio | -1.18 |
| EPS | $-1.45 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.19 |
| 52-Week Low | $0.61 |
| Volume | 10 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-236.93M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0 | $-236.93M | $-1.45 |
| 2023 | $0 | $-235.93M | $-3.63 |
7 analysts cover NMRA: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.33.